Synthesis and biological evaluation of certain 3-substituted benzylideneamino-2-(4-nitrophenyl)quinazolin-4(3H)-one derivatives

References

• Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641–7
   PubMed Web of Science ®Google Scholar
• Minami T, Tojo H, Shinomura Y, et al. Raised serum activity of phospholipase A2 immunochemically related group II enzyme in inflammatory bowel disease: its correlation with disease activity of Crohn’s disease and ulcerative colitis. Gut 1992;33:914–21
   PubMedGoogle Scholar
• Bohe M. Pancreatic and granulocytic endoproteases in faecal extracts from patients with active ulcerative colitis. Scand J Gastroenterol 1987;22:59–64
   PubMed Web of Science ®Google Scholar
• Hargreaves KR, Kropinski AM, Clokie MR. What does the talking? Quorum sensing signalling genes discovered in a bacteriophage genome. PLoS One 2014;24;9:e85131
   Google Scholar
• Cooksley CM, Davis IJ, Winzer K, et al. Regulation of neurotoxin production and sporulation by a Putative agrBD signaling system in proteolytic Clostridium botulinum. Appl Environ Microbiol 2010;76:4448–60
   PubMed Web of Science ®Google Scholar
• Sleebs BE, Czabotar PE, Fairbrother WJ, et al. Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra-long with potent proapoptotic cell-based activity. J Med Chem 2011;54:1914–26
   PubMed Web of Science ®Google Scholar
• Koller M, Lingenhoehl K, Schmutz M, et al. Quinazolinedione sulfonamides: a novel class of competitive AMPA receptor antagonists with oral activity. Bioorg Med Chem Lett 2011;21:3358–61
   PubMed Web of Science ®Google Scholar
• Paick JS, Cho MC, Song SH, et al. Impacts of the quinazoline-based alpha1-antagonist, terazosin, and of the sulfonamide derivative, tamsulosin, on serum prostate-specific antigen and prostate volume. J Korean Med Sci 2008;23:509–13
   Google Scholar
• Stutzmann JM, Vuilhorgne M, Mignani S. Synthesis and structure-activity relationships of 4,10-dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazine derivatives: highly potent and selective AMPA receptor antagonists with in vivo activity. Mini Rev Med Chem 2004;4:123–40
   Google Scholar
• Spanò V, Montalbano A, Carbone A, et al. Synthesis of a new class of pyrrolo[3,4-h]quinazolines with antimitotic activity. Eur J Med Chem 2014;74:340–57
   Google Scholar
• Li Z, Tan JH, He JH, et al. Disubstituted quinazoline derivatives as a new type of highly selective ligands for telomeric G-quadruplex DNA. Eur J Med Chem 2012;47:299–311
   PubMedGoogle Scholar
• Barraja P, Caracausi L, Diana P, et al. Pyrrolo[3,2-h]quinazolines as photochemotherapeutic agents. Chem Med Chem 2011;6:1238–48
   Google Scholar
• Traquandi G, Ciomei M, Ballinari D, et al. Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors. J Med Chem 2010;53:2171–87
   PubMed Web of Science ®Google Scholar
• Buck WB, Osweiter GD, VanGelder AG. In clinical and diagnostic veterinary toxicology. 2nd ed. Dubuque (IA): Kendall, Hunt Publishing Co.; 1976
   Google Scholar
• Sharon P, Stenson WF. Metabolism of arachidonic acid in acetic acid induced colitis in rats. Gastroenterology 1985;88:55–63
   PubMed Web of Science ®Google Scholar
• Mustafa A, El-Medany A, Hagar HH, El-Medany G. Ginkgo biloba attenuates mucosal damage in a rat model of ulcerative colitis. Pharmacol Res 2006;53:324–30
   PubMed Web of Science ®Google Scholar
• Thippeswamy BS, Mahendran S, Biradar MI, et al. Protective effect of embelin against acetic acid induced ulcerative colitis in rats. Eur J Pharmacol 2011;654:100–5
   PubMed Web of Science ®Google Scholar
• Fabia R, Ar’Rajab A, Willén R, et al. Effect of putative phospholipase A2 inhibitors on acetic acid-induced acute colitis in the rat. Br J Surg 1993;80:1199–204
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Sugimura K, Ishizuka K, et al. Correlation between serum phospholipase A(2) IIA levels and histological activity in patients with ulcerative colitis. Int J Colorectal Dis 2002;17:311–16
   Google Scholar
• Bohe M, Genell S, Ohlsson K. Protease inhibitors in plasma and faecal extracts from patients with active inflamatory bowel disease. Scand J Gastroenterol 1986;21:598–604
   PubMed Web of Science ®Google Scholar
• Hawkins JV, Emmel EL, Feuer JJ, et al. Protease activity in a hapten-induced model of ulcerative colitis in rats. Dig Dis Sci 1997;42:1969–80
   PubMed Web of Science ®Google Scholar
• Playford RJ, Hanby AM, Patel K, Calam J. Infuence of inflammatory bowel disease on the distribution and concentration of pancreatic secretory trypsin inhibitor within the colon. Am J Pathol 1995;146:310–16
   Google Scholar
• Senda SY, Fujiyama Y, Bamba T, Hosoda S. Treatment of ulcerative colitis with camostat mesilate, a serine protease inhibitor. Intern Med 1993;32:350–4
   PubMed Web of Science ®Google Scholar
• Bogert MT, Gortner RA, Amend CG. Researches on quinazolines. XXVII. Synthesis of 3-aminoaryl-4-quinazolones from acylanthranils and aromatic diamines. J Am Chem Soc 1911;33:949–62
   Google Scholar
• Verma M, Singh S, Singh, KN. Synthesis of some new benzoxazine derivatives of biological interest. Heterocyclic Comm 2003;9:499–502
   Google Scholar
• Ecobichon DJ. The basis of toxicity testing. 3rd ed. New York: CRC Press;1984:43–86
   Google Scholar
• Mascolo N, Izzo A, Autore G, et al. Acetic acid-incluced colitis in in normal and essential fatty acid deficient rats. J Pharmacol 1995;272:469–75
   Google Scholar
• Kunitz, M. Crystalline soyabean trypsin inhibitor II. General properties. J Gen Physiol 1947;30:291–310
   PubMed Web of Science ®Google Scholar
• De Araújo AL, Radvanyi F. Determination of phospholypase A2 activity by a colorimetric assay using a pH indicator. Toxicon 1987;25:1181–8
   Google Scholar